02563nas a2200229 4500008004100000245012400041210006900165260001400234300001200248490000700260520183900267653003302106653002402139653002702163653001402190653001402204100002502218700001902243700001702262700001802279856003602297 2020 eng d00aHuman Umbilical Cord Blood-derived Secretome Enhance Endothelial Progenitor Cells Migration on Hyperglycemic Conditions0 aHuman Umbilical Cord Bloodderived Secretome Enhance Endothelial  cJune 2020 a793-7970 v123 a

Hyperglycemia state is harmful to body’s homeostasis. Uncontrolled hyperglycemic patients, especially patients with diabetes mellitus have a higher mortality risk of heart disease 2 to 4 times compared to non-hyperglycemic patients. Vascular endothelial impairment always been observed and found as a key feature of hyperglycemia state, which is correlated with reduced numbers and dysfunction of endothelial progenitor cells (EPCs). Objective: This paper aims to investigate the effect of hUCB-MSCs derived secretome treatment on the EPCs migration under hyperglycemia state. Materials and Methods: EPCs were isolated and cultured from peripheral blood samples and cultured for three days. Cultured EPCs were cultivated in 6-well plates until confluence and incubated with high glucose for 5 days, then placed in the modified Boyden chamber at the upper chamber with basal media. The lower chamber was supplemented with basal media and secretome at 2%, 10%, and 20% concentration and VEGF treated group as a control. EPCS migration was evaluated using a Boyden chamber assay. Statistical analysis was performed using SPS 25.0. Results: EPCs migration were significantly higher when hUCB-MSCs-derived secretome was given in high glucose concentrations compared to the and control group (79.80 ± 5.07 vs 51.00 ± 5.15, p<0.000). This study also showed that hUCB-MSCs-derived secretome increase EPCs migration under high glucose concentrations in a dose-dependent manner (p<0.05). Conclusion: hUCB-MSCsderived secretome enhances EPCs migration under hyperglycemic state. This result may be of relevance for cell-free and regenerative therapeutic modality for a diabetic patient with coronary artery disease (CAD).

10aEndothelial progenitor cells10aHyperglycemia state10aMesenchymal stem cells10aMigration10aSecretome1 aOktaviono, Yudi, Her1 aSusanti, Melly1 aLefi, Achmad1 aSandra, Ferry uhttps://phcogj.com/article/1178